Table 2.

Summary of key inflammasome targeting therapeutics in development

Therapeutic agent or class	Mechanism of action	Stage	References
MCC950 series and Inzomelid	Covalent NLRP3 inhibitor	Clinical	[12, 121] NCT04015076
Belnacasan (VX-765)	Caspase-1 inhibitor	Clinical	[122] NCT01501383
Fenamates	Inhibits ASC specks, caspase-1 activation, microglial activation	Preclinical	[119, 131]
Glibenclamide	NLRP3 inhibitor	Preclinical	[28]
BAY 11-7082	Inhibits ATPase activity of NLRP3	Preclinical	[132]
OTL1177	Inhibits NLRP3-ASC and NLRP3-caspase-1 interactions	Preclinical	[120]
3,4-methylenedioxy-b-nitrostyrene	Prevents NLRP3 ATPase activity	Preclinical	[116]
JC-171	Prevents NLRP3 activation and IL1β release	Preclinical	[117]
BOT-4-ene	Impairs ATPase activity of NLRP3	Preclinical	[114]
Parthenolide	Inhibits inflammasome priming through IκBα blockade and NFκB inhibition	Preclinical	[115]
Fc11a-2	Decreases proinflammatory cytokine secretion	Preclinical	[118]